季秀峰,石莉,邓意辉
JI Xiu-feng1,SHI Li2,DENG Yi-hui1(1.School of Pharmacy

• 1:沈阳药科大学药学院
• 2:辽宁省药物研究院

摘要(Abstract)：

目的综述白蛋白纳米粒作为药物传递系统的最新研究进展。方法依据国内外研究文章及专利文献共63篇,将白蛋白的性质及功能、白蛋白纳米粒的制备工艺、靶向肿瘤作用机理、上市药物及其临床前和临床实验结果进行了概括。结果白蛋白是一种良好的药物载体,显示独特的靶向肿瘤机理;白蛋白纳米粒的制备方法中二硫键形成法相对于其他制备方法具有显著优点,避免了很多基于溶剂传递的传统剂型中存在的潜在问题,由其制备的上市药物紫杉醇白蛋白纳米粒(Abraxane)具有较好的临床疗效。结论白蛋白纳米粒给药系统的研究有着重要的临床意义及发展前景。
Objective To review the new research development of the albumin nanoparticles as a drug delivery system.Methods According to the recent relevant literature and patents,this article summarized the transport properties of albumin,the production technique about albumin nanoparticles and its novel targeting tumours mechanism.Recently,nanoparticle albumin-bound paclitaxel(nab-paclitaxel;Abraxane)has been approved for the treatment of metastatic breast cancer in 2005,and its preclinical and clinical studies were also reviewed.Results Albumin is playing an increasing role as a drug carrier in the clinical setting.And albumin drug delivery systems exploit natural albumin receptor-mediated(gp60)endothelial transcytosis pathways to selectively deliver drugs to tumors.Nanoparticle albumin-bound technology shows more obvious advantages than other methods on albumin nanoparticles preparation,which avoiding many potential drawbacks of solvent-based formulations in the traditional forms.And abraxanehas demonstrated utility in the setting of cancer chemotherapy.Conclusions The Albumin nanoparticles drug delivery system displays a promising prospect in the pharmaceutical field.

关键词(KeyWords)： 白蛋白纳米粒;载药系统;制备工艺;nabTM-技术;紫杉醇;临床结果
albumin nanoparticle;drug delivery system;preparation technology;nabTM-tecnology;paclitaxel;clinical study

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 季秀峰,石莉,邓意辉
JI Xiu-feng1,SHI Li2,DENG Yi-hui1(1.School of Pharmacy

DOI: 10.14066/j.cnki.cn21-1349/r.2010.12.005

参考文献(References)：

• [1]TORCHILIN V P,BERDICHEVSKY R,BARSUKOV AA,et al.Coating liposomes with protein decreased theircapture by macrophages[J].FEBS Lett,1980,111:184?188.
• [2]DESAI N.Nab technology:A drug delivery platformutilising endothelial gp60 receptor-based transport andtumour-derived SPARC for targeting[J].Drug DeliveryReport,2007,16:37-41.
• [3]赵颖怡,汪嵘,韦宇托,等.人血清白蛋白的研究进展[J].广西农业生物科学,2002,21(2):126-128.
• [4]KRATZ F.Albumin as a drug carrier:design of pro-drugs,drug conjugates and nanoparticles[J].J ControlRelease,2008,132(3):171-183.
• [5]CARTER D C,HE X M,MUNSONS H,et al.Three-di-mensional structure of human serum albumin[J].Sci-ence,1989,244(4909):1195-1198.
• [6]BERTUCCI C,DOMENICI E.Reversible and covalentbinding of drugs to human serum albumin:methodologi-cal approaches and physiological relevance[J].CurrMed Chem,2002,9(15):1463-1481.
• [7]PETERS T.Serum albumin[J].Adv Protein Chem,1985,37:161-245.
• [8]MENDEZ C M,MCCLAIN C J,MARSANO L S.Albu-min therapy in clinical practice[J].Nutr Clin Pract,2005,20(3):314-320.
• [9]BABSON A L,WINNICK T.Protein transfer intumor-bearing rats[J].Cancer Res,1954,14:606-611.
• [10]MATSUMURA Y,MAEDA H.A new concept for mac-romolecular therapeutics in cancer chemotherapy:mechanism of tumoritropic accumulation of proteins andthe antitumor agent smancs[J].Cancer Res,1986,46:6387-6392.
• [11]MAEDA H,WUJ,SAWA T,et al.Tumor vascular per-meability and the EPR effect in macromolecular thera-peutics:a review[J].J Control Release,2000,65(1-2):271-284.
• [12]KRATZ F,BEYER U.Serum proteins as drug carriersof anticancer agents:a review[J].Drug Deliv,1998,5(4):281-299.
• [13]STEHLE G,SINN H,WUNDER A,et al.Plasma pro-tein(albumin)catabolism by the tumor itself-implica-tions for tumor metabolism and the genesis of cachexia[J].Crit Rev Oncol Hemat,1997,26(2):77-100.
• [14]WUNDER A,MULLER U L,STELZER E H,et al.Al-bumin-based drug delivery as novel therapeutic ap-proach for rheumatoid arthritis[J].The Journal of im-munology,2003,170:4793-4801.
• [15]JONES C,BURTON M A,GRAY B N.Albumin mico-spheres as vehicles for the sustained and microcon-trolled release of doxorubicin[J].J Pharm Pharmacol,1989,41:813-816.
• [16]WARTLICK H,BIRGIT S S,STREBHARDT K,et al.Tumour cell delivery of antisense oligonucleotides byhuman serum albumin nanoparticles[J].J Control Re-lease,2004,96(3):483-495.
• [17]廖工铁.靶向给药制剂[M].成都:成都科技出版社,1997:17-20.
• [18]CHENG Q,LINW,COOMBES AG,et a1.Preparationof human serum albumin microspheres by a novel ace-tone-heat denaturation method[J].Microencapsul,l994,11(4):395-407.
• [19]WEBER C,KREUTER J,LANGER K.Desolvationprocess and surface characteristics of HSA-nanoparti-cles[J].Int J Pharm,2000,196(2):197-200.
• [20]LANGER K,BALTHASAR S,VOGEL V,et al.Optimi-zation of the preparation process for human serum albu-min(HSA)nanoparticles[J].Int J Pharm,2003,257(1-2):169-180.
• [21]STEINHAUSER I,SPANKUCH B,STREBHARDT K,et al.Trastuzumab-modified nanoparticles:optimisationof preparation and uptake in cancer cells[J].Biomate-rials,2006,27(28):4975-4983.
• [22]M LLER B G,LEUENBERGER H,KISSEL T,et al.Albumin nanospheres as carriers for passive drug targe-ting:an optimized manufacturing technique[J].Phar-maceutical Research Pharm Res,1996,13(1):32-37.
• [23]LIN W,COOMBES A G A,DAVIES MC,et al.Prepa-ration of sub 100 nm human serum albumin nanosph-eres using a pH-coacervation method[J].J Drug Targe-ting,1993,1(3):237-243.
• [24]LINWu,GARNETTMC,DAVIES MC,et al.Prepara-tion of surface-modified albumin nanospheres[J].Bio-materials,1997,18(7):559-565.
• [25]LIN Wu,GARNETT M C,DAVIS S S,et al.Prepara-tion and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles[J].J Control Release,2001,71(1):117-126.
• [26]SANTHI K,DHANARAJ S A,RAJENDRAN S D,etal.Nonliposomal approach-Astudy of preparation of eggalbumin nanospheres containing amphotericin-B[J].Drug Development and Industrial Pharmacy,1999,25(4):547-551.
• [27]MERODIO M,ARNEDO A,RENEDO M J,et al.Gan-ciclovir-loaded albumin nanoparticles:characterizationand in vitro release properties[J].Eur J Pharm Sci,2001,12(3):251-259.
• [28]MEZIANI M J,SUN Ya-ping.Protein-conjugated nano-particles from rapid expansion of supercritical fluid so-lution into aqueous solution[J].J Am Chem Soc,2003,125(26):8015-8018.
• [29]内尔.P.代赛,陶春林,安杰.杨赖斯烈.路易,等.蛋白质稳定的药理活性物质及其它的制备和应用方法:中国,97199720.9[P].1997-9-24.
• [30]DENG Yi-hui,DONG Xiao-hui,SHI Li,et al.A drugdelivery system,its preparation process and use:WO,2009-092291[P].2009-06-07.
• [31]邓意辉,王宁.含有蛋白的葫芦素纳米制剂及制备方法和用途:中国,1919339A[P].2007-2-28.
• [32]王宁,邓意辉,王绍宁,等.高效液相色谱法测定葫芦素B人血清白蛋白纳米粒中药物含量[J].中国新药杂志,2007,16(23):1968-1970.
• [33]刘欣荣,王龙,卢懿,等.HPLC法测定羟基喜树碱人血清白蛋白纳米粒中的药物含量[J].沈阳药科大学学报,2009,26(1):48-51.
• [34]卢懿,邓意辉,徐缓,等.半胱氨酸对高效液相色谱法测定多西紫杉醇白蛋白纳米粒含量的影响[J].分析化学研究简报,2008,36(9):1265-1268.
• [35]石莉,邓意辉,董晓辉,等.超声法制备齐多夫定碳酸胆固醇酯牛血清白蛋白纳米粒[J].沈阳药科大学学报,2008,25(10):759-764.
• [36]张辉,霍美蓉,周建平,等.伊曲康唑白蛋白混悬剂的制备和表征[J].中国药科大学学报,2008,39(6):510-514.
• [37]SCHNITZER J E.Gp60 is an albumin-binding glyco-protein expressed by continuous endothelium involvedin albumin transcytosis[J].Am J Physiol-Heart C,1992,262(1):246-254.
• [38]HAWKINS M J,SOON-SHIONG P,DESAI N,et al.Protein nanoparticles as drug carriers in clinical medi-cine[J].Adv Drug Deliver Rev,2008,60(8):876-885.
• [39]SAGE H,JOHNSON C,BORNSTEIN P.Characteriza-tion of a novel serum albumin-binding glycoprotein se-creted by endothelial cells in culture[J].J Bio Chem,1984,259(6):3993-4007.
• [40]FRAMSON P E,SAGE E H.SPARC and tumorgrowth:where the seed meets the soil?[J].J Cell Bio-chem,2004,92(4):679-690.
• [41]WANI M C,TAYLOR H L,WALL M E,et al.Plantantitumor agents.VI.Isolation and structure of taxol,anovel antileukemic and antitumor agent from Taxus bre-vifolia[J].J Am Chem Soc,1971,93(9):2325-2327.
• [42]ADAMS J D,FLORA K P,GOLDSPIEL B R,et al.Taxol:a history of pharmaceutical development and cur-rent pharmaceutical concerns[J].Natl Cancer InstMonogr,1993,15(2):141-147.
• [43]RIONDEL J,JACROT M,PICOT F,et al.Therapeuticresponse to taxol of six human tumors xenografted intonude mice[J].Cancer Chemother Pharmacol,1986,17(2):137-142.
• [44]ROWINSKY R K,DONEHOWER R C.Paclitaxel(Taxol)[J].N Engl J Med,1995,332:1004-1014.
• [45]TIJE A J,VERWEIJ J,LOOS W J,et al.Pharmacologi-cal effects of formulation vehicles:implications forcancer chemotherapy[J].Clin Pharmacokinet,2003,42(7):665-685.
• [46]BROUWER E,VERWEIJ J,BRUIJN D,et al.Meas-urement of fraction unbound paclitaxel in human plas-ma[J].Drug Metab Dispos,2000,28(10):1141-1145.
• [47]MILLWARD M J,WEBSTER L K,RISCHIN D,et al.Phase I trial of Cremophor EL with bolus doxorubicin[J].Clin Cancer Res,1998,4:2321-2329.
• [48]HOLMES F A,ROWINSKY E K.Pharmacokinetic pro-files of doxorubicin in combination with taxanes[J].Se-min Oncol,2001,28(12):8-14.
• [49]WEISS R B,DONEHOWER R C,WIERNIK P H,etal.Hypersensitivity reactions from taxol[J].J Clin On-col,1990,8:1263-1268.
• [50]SPARREBOOM A,ZUYLEN L V,BROUWER E,etal.Cremophor EL-mediated alteration of paclitaxel dis-tribution in human blood:clinical pharmacokinetic im-plications[J].Cancer Res,1999,59:1454-1457.
• [51]SHARMAA,MAYHEW E,BOLCSAK L,et al.Activityof paclitaxel liposome formulations against human ovari-an tumor xenografts[J].Int J Cancer,1997,71(1):103-107.
• [52]TERWOGTJ M,NUIJENB,HUININK W W,et al.Al-ternative formulations of paclitaxel[J].Cancer TreatRev,1997,23(2):87-95.
• [53]SINGLA A K,GARG A,AGGARWAL D.Paclitaxeland its formulations[J].Int J Pharm,2002,235(1-2):179-192.
• [54]DESAI N,TRIEUV,YANG A,et al.Enhanced efficacyand safety of nanoparticle ablbunin-bound nab-docetaelversus taxotere[C]//The 97th Amual Mecting of theAmerican Association for Cancer Research,April 1-5,2006.Washington,D.C.:The American Association forCauer Research,2006.
• [55]DESAI N,TRIEUV,YAO Z,et al.Increased antitumoractivity,intratumor paclitaxel concentrations,and endo-thelial cell transport of cremophor-free,albumin-boundpaclitaxel,ABI-007,compared with cremophor-basedpaclitaxel[J].Clin Cancer Res,2006(4):1317-1324.
• [56]IBRAHIM N K,DESAI N,LEGHA S,et al.Phase Iand pharmacokinetic study of ABI-007,a cremophor-free,protein-stabilized,nanoparticle formulation of pa-clitaxel[J].Clin Cancer Res,2002(8):1038-1044.
• [57]滕小玉,管忠震,姚志文,等.晚期实体癌患者对不含聚氧乙烯蓖麻油注射用紫杉醇白蛋白纳米粒悬浮液的临床耐受性研究[J].癌症,2004,23(11):1431-1436.
• [58]IBRAHIM N K,SAMUELS B,PAGE R,et al.Multi-center phase II trial of ABI-007,an albumin-bound pa-clitaxel,in women with metastatic breast cancer[J].JClin Oncol,2005,23(25):6019-6026.
• [59]GRADISHAR W J,TJULANDIN S,DAVIDSON N,etal.Phase III trial of nanoparticle albumin-bound pacli-taxel compared with polyethylated castor oil-based pa-clitaxel in women with breast cancer[J].J Clin Oncol,2005,23(31):7794-7803.
• [60]ASPITIA A M,PEREZ E A.North central cancer treat-ment group N0531:Phase II trial of weekly albumin-bound paclitaxel(ABI-007;Abraxane)in combinationwith gemcitabine in patients with metastatic breastcancer[J].Clin Breast Cancer,2005,6(4)361-364.
• [61]SOMER B G,SCHWARTZBERG L S,ARENA F,etal.Phase II trial of nab-paclitaxel(nanoparticle albu-min-bound paclitaxel(ABX))+capecitabine(XEL)infirst-line treatment of metastatic breast cancer(MBC)[J/OL].J Clin Oncol,2007 ASCO Annual MeatingProceedings,2007,25(18S):1053[2010-08-10].http://meeting.ascopubs.org/untent/vol 25/18_sup-pl/htm.
• [62]REYNOLDS C,BARRERAD,VUD Q,et al.An open-label,phase II trial of nanoparticle albumin bound pa-clitaxel(nab-paclitaxel),carboplatin and bevacizumabin first-line patients with advanced non-squamous non-small cell lung cancer(NSCLC)[J/OL].J Clin Oncol,2007 ASCO Annual Meating Proceedings,2007,25(18S):7610[2010-08-10].http://meeting.asco-pubs.org/untent/vol 25/18_suppl/htm.
• [63]TENERIELLO M G,TSENG P C,CROZIER M,et al.Results of a phase II evaluation of nanoparticle albuminbound paclitaxel(nabpaclitaxel)in platinum-sensitivepatients with recurrent ovarian,peritoneal,or fallopiantube cancer[J/OL].J Clin Oncol,2007 ASCO AnnualMeating Proceedings,2007,25(18S):5525[2010-08-10].http://meeting.ascopubs.org/untent/vol 25/18_suppl/htm.